Uncategorized

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Published

3 hours ago

May 4, 2026

Temp User

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Related Topics:

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

The old and New Edition cast comes together to perform

Helixgate

Uncategorized

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

Leave a Reply

Leave a Reply

Trending

Leave a Reply Cancel reply

Leave a Reply

Trending

Leave a Reply